Real-time index price for TSX Oil and Gas EW Index (TXOE), along with buy or sell indicators, analysis, charts, historical ...
A %Healthcare company based out of Pennsylvania caused quite the stir on Tuesday after the company announced that it had ...
On Monday, Aclaris Therapeutics, Inc. (NASDAQ:ACRS) entered into an exclusive license agreement with Biosion Inc for ...
Silence Therapeutics' Phase 2 data shows zerlasiran achieves over 80% Lp(a) reduction in ASCVD patients but faces dosing ...
Under the agreement, Biosion will receive over $40 million cash as an upfront license fee and reimbursement for certain development costs and drug product materials. Biosion said it will receive 19.9% ...
Aclaris (ACRS) soared 60% Tuesday, the day after the company announced it was licensing two drug candidates, prompting ...
Stocktwits on MSN6h
Aclaris Therapeutics Stock Surges On Licensing Deal, $80 Million Private Placement: Retail Sentiment JumpsAclaris Therapeutics ($ACRS) stock rose more than 46% on Tuesday after the clinical-stage biopharmaceutical company entered ...
Aclaris Therapeutics has secured an exclusive licence from Biosion for the global rights to two new antibodies, BSI-045B and ...
Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...
Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...
WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage ...
Fintel on MSN11h
BTIG Upgrades Aclaris Therapeutics (ACRS)Fintel reports that on November 19, 2024, BTIG upgraded their outlook for Aclaris Therapeutics (NasdaqGS:ACRS) from Neutral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback